382 related articles for article (PubMed ID: 15034571)
1. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice.
Kieran D; Kalmar B; Dick JR; Riddoch-Contreras J; Burnstock G; Greensmith L
Nat Med; 2004 Apr; 10(4):402-5. PubMed ID: 15034571
[TBL] [Abstract][Full Text] [Related]
2. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis.
Phukan J
IDrugs; 2010 Jul; 13(7):482-96. PubMed ID: 20582873
[TBL] [Abstract][Full Text] [Related]
3. Arimoclomol: a potential therapy under development for ALS.
Lanka V; Wieland S; Barber J; Cudkowicz M
Expert Opin Investig Drugs; 2009 Dec; 18(12):1907-18. PubMed ID: 19938902
[TBL] [Abstract][Full Text] [Related]
4. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS.
Kalmar B; Novoselov S; Gray A; Cheetham ME; Margulis B; Greensmith L
J Neurochem; 2008 Oct; 107(2):339-50. PubMed ID: 18673445
[TBL] [Abstract][Full Text] [Related]
5. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.
Kalmar B; Lu CH; Greensmith L
Pharmacol Ther; 2014 Jan; 141(1):40-54. PubMed ID: 23978556
[TBL] [Abstract][Full Text] [Related]
6. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.
Turner BJ; Talbot K
Prog Neurobiol; 2008 May; 85(1):94-134. PubMed ID: 18282652
[TBL] [Abstract][Full Text] [Related]
7. [Amyotrophic lateral sclerosis: recent insights from transgenic animal models with SOD1 mutations].
Aoki M
Rinsho Shinkeigaku; 2004 Nov; 44(11):788-91. PubMed ID: 15651292
[TBL] [Abstract][Full Text] [Related]
8. Treatment with a coinducer of the heat shock response delays muscle denervation in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.
Kalmar B; Edet-Amana E; Greensmith L
Amyotroph Lateral Scler; 2012 Jun; 13(4):378-92. PubMed ID: 22591194
[TBL] [Abstract][Full Text] [Related]
9. The metabolic hypothesis in amyotrophic lateral sclerosis: insights from mutant Cu/Zn-superoxide dismutase mice.
Gonzalez de Aguilar JL; Dupuis L; Oudart H; Loeffler JP
Biomed Pharmacother; 2005 May; 59(4):190-6. PubMed ID: 15862714
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the structure of the Golgi apparatus and the function of the secretory pathway by mutants G93A and G85R of Cu, Zn superoxide dismutase (SOD1) of familial amyotrophic lateral sclerosis.
Stieber A; Gonatas JO; Moore JS; Bantly A; Yim HS; Yim MB; Gonatas NK
J Neurol Sci; 2004 Apr; 219(1-2):45-53. PubMed ID: 15050437
[TBL] [Abstract][Full Text] [Related]
11. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
Cervetto C; Frattaroli D; Maura G; Marcoli M
Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
[TBL] [Abstract][Full Text] [Related]
12. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis.
Yoo YE; Ko CP
Exp Neurol; 2011 Sep; 231(1):147-59. PubMed ID: 21712032
[TBL] [Abstract][Full Text] [Related]
13. Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: a longitudinal MRI study.
Marcuzzo S; Zucca I; Mastropietro A; de Rosbo NK; Cavalcante P; Tartari S; Bonanno S; Preite L; Mantegazza R; Bernasconi P
Exp Neurol; 2011 Sep; 231(1):30-7. PubMed ID: 21620832
[TBL] [Abstract][Full Text] [Related]
14. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model.
Sunyach C; Michaud M; Arnoux T; Bernard-Marissal N; Aebischer J; Latyszenok V; Gouarné C; Raoul C; Pruss RM; Bordet T; Pettmann B
Neuropharmacology; 2012 Jun; 62(7):2346-52. PubMed ID: 22369784
[TBL] [Abstract][Full Text] [Related]
15. Selective loss of alpha motoneurons innervating the medial gastrocnemius muscle in a mouse model of amyotrophic lateral sclerosis.
Mohajeri MH; Figlewicz DA; Bohn MC
Exp Neurol; 1998 Apr; 150(2):329-36. PubMed ID: 9527903
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of heat shock protein 27 in a model of ALS occur in the early stages of disease progression.
Sharp PS; Akbar MT; Bouri S; Senda A; Joshi K; Chen HJ; Latchman DS; Wells DJ; de Belleroche J
Neurobiol Dis; 2008 Apr; 30(1):42-55. PubMed ID: 18255302
[TBL] [Abstract][Full Text] [Related]
17. Treatment with an antibody directed against Nogo-A delays disease progression in the SOD1G93A mouse model of Amyotrophic lateral sclerosis.
Bros-Facer V; Krull D; Taylor A; Dick JR; Bates SA; Cleveland MS; Prinjha RK; Greensmith L
Hum Mol Genet; 2014 Aug; 23(16):4187-200. PubMed ID: 24667415
[TBL] [Abstract][Full Text] [Related]
18. Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models.
Kuta R; Larochelle N; Fernandez M; Pal A; Minotti S; Tibshirani M; St Louis K; Gentil BJ; Nalbantoglu JN; Hermann A; Durham HD
Cell Stress Chaperones; 2020 Jan; 25(1):173-191. PubMed ID: 31900865
[TBL] [Abstract][Full Text] [Related]
19. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.
Lambrechts D; Storkebaum E; Morimoto M; Del-Favero J; Desmet F; Marklund SL; Wyns S; Thijs V; Andersson J; van Marion I; Al-Chalabi A; Bornes S; Musson R; Hansen V; Beckman L; Adolfsson R; Pall HS; Prats H; Vermeire S; Rutgeerts P; Katayama S; Awata T; Leigh N; Lang-Lazdunski L; Dewerchin M; Shaw C; Moons L; Vlietinck R; Morrison KE; Robberecht W; Van Broeckhoven C; Collen D; Andersen PM; Carmeliet P
Nat Genet; 2003 Aug; 34(4):383-94. PubMed ID: 12847526
[TBL] [Abstract][Full Text] [Related]
20. Genetic inroads in familial ALS.
Shaw PJ
Nat Genet; 2001 Oct; 29(2):103-4. PubMed ID: 11586285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
